m6A-related lncRNAs are potential biomarkers for the prognosis of COAD patients

Xu, Chenyang; He, Tingting; Shao, Xinxin; Gao, Ling; Cao, Lei

doi:10.3389/fonc.2022.920023

Cited by 4 publications

(3 citation statements)

References 36 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRLncRI consists of three high-risk lncRNA, AC004846.1, AL391422.4, and UBA6-AS1. Previous studies have shown that UBA6-AS1 can inhibit the proliferation ability of CRC cells in vitro and is associated with poorer prognosis (35). This is consistent with the results of this study and also reflects the accuracy of this study.…”

Section: Discussionsupporting

confidence: 93%

Construction and validation of a metabolic-associated lncRNA risk index for predicting colorectal cancer prognosis

Lin

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMetabolic reprogramming is one of the most important events in the development of tumors. Similarly, long non-coding RNAs are closely related to the occurrence and development of colorectal cancer (CRC). However, there is still a lack of systematic research on metabolism-related lncRNA in CRC.MethodsExpression data of metabolism-related genes and lncRNA were obtained from The Cancer Genome Atlas (TCGA). Hub metabolism-related genes (HMRG) were screened out by differential analysis and univariate Cox analysis; a metabolism-related lncRNA risk index (MRLncRI) was constructed by co-expression analysis, univariate Cox regression analysis, LASSO, and multivariate Cox regression analysis. Survival curves were drawn by the Kaplan-Meier method. The ssGSEA method assessed the tumor microenvironment of the sample, and the IPS assessed the patient’s response to immunotherapy. “Oncopredict” assessed patient sensitivity to six common drugs.ResultsMRLncRI has excellent predictive ability for CRC prognosis. Based on this, we also constructed a nomogram that is more suitable for clinical applications. Most immune cells and immune-related terms were higher in the high-risk group. IPS scores were higher in the high-risk group. In addition, the high-risk and low-risk groups were sensitive to different drugs.ConclusionMRLncRI can accurately predict the prognosis of CRC patients, is a promising biomarker, and has guiding significance for the clinical treatment of CRC.

show abstract

Section: Discussionsupporting

confidence: 93%

Construction and validation of a metabolic-associated lncRNA risk index for predicting colorectal cancer prognosis

Lin

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…AL122125.1 emerged as an independent prognostic factor, providing novel information about LUSC risk-stratification ( 63 ). Similar approach has also been applied for the analysis of bladder, colon cancers, hepatocellular carcinoma and hematological malignancies, in particular like acute myelocytic leukemia ( 28 , 64 – 73 , 77 , 78 ).…”

Section: M6a-related Lncrnas Signaturesmentioning

confidence: 99%

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer

et al. 2023

View full text Add to dashboard Cite

Most of our transcribed RNAs are represented by non-coding sequences. Long non-coding RNAs (lncRNAs) are transcripts with no or very limited protein coding ability and a length >200nt. They can be epigenetically modified. N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5-methylcytosine (m5C), 7-methylguanosine (m7G) and 2’-O-methylation (Nm) are some of the lncRNAs epigenetic modifications. The epigenetic modifications of RNA are controlled by three classes of enzymes, each playing a role in a specific phase of the modification. These enzymes are defined as “writers”, “readers” and “erasers”. m6A and m5C are the most studied epigenetic modifications in RNA. These modifications alter the structure and properties, thus modulating the functions and interactions of lncRNAs. The aberrant expression of several lncRNAs is linked to the development of a variety of cancers and the epigenetic signatures of m6A- or m5C-related lncRNAs are increasingly recognized as potential biomarkers of prognosis, predictors of disease stage and overall survival. In the present manuscript, the most up to date literature is reviewed with the focus on m6A and m5C modifications of lncRNAs and their significance in cancer.

show abstract

“…Furthermore, these experiments demonstrated that AC013652.1 and MCM3AP-AS1 inhibit disulfidptosis. LncRNAs have emerged as promising targets for cancer diagnosis, treatment, and prognosis, including in COAD [ 33 – 35 ]. Previous studies have reported the tumor-promoting roles of lncRNAs AC013652.1 and MCM3AP-AS1 in various cancers.…”

Section: Discussionmentioning

confidence: 99%

Establishment of disulfidptosis-related LncRNA signature as biomarkers in colon adenocarcinoma

Yao,

Liu,

Yao

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Purpose Metabolic reprogramming is a hallmark of cancer and plays a key role in precision oncology treatment. Long non-coding RNAs (lncRNAs) regulate cancer cell behavior, including metabolism. Disulfidptosis, a newly identified form of regulated cell death triggered by glucose starvation, has yet to be fully understood in colon adenocarcinoma (COAD). This study aimed to confirm the existence and role of disulfidptosis in COAD and identify disulfidptosis-related lncRNAs that may be targeted to induce disulfidptosis in COAD. Methods PI and F-actin staining were used to observe disulfidptosis in COAD cell lines. Disulfidptosis-related lncRNAs were identified based on the expression of disulfidptosis-associated genes in the TCGA-COAD database. A four-lncRNA signature for disulfidptosis was established. Subsequently, loss-of-function assays explored the roles of AC013652.1 and MCM3AP-AS1 in disulfidptosis. Results Disulfidptosis was observed in COAD cells under glucose starvation and could be reversed by agents that prevent disulfide stress, such as dithiothreitol (DTT) and tris-(2-carboxyethyl)-phosphine (TCEP). The prognostic value of disulfidptosis-associated genes in COAD patients was confirmed, with higher expression indicating longer survival. A disulfidptosis-related lncRNA signature comprising four lncRNAs was established based on the expression of these genes. Among these, AC013652.1 and MCM3AP-AS1 predicted worse prognoses. Furthermore, inhibiting AC013652.1 or MCM3AP-AS1 increased disulfidptosis-associated gene expression and cellular death, which could be reversed by DTT and TCEP. Conclusions This study provides hitherto undocumented evidence of the existence of disulfidptosis and the prognostic value of disulfidptosis-associated genes in COAD. Importantly, we identified lncRNAs AC013652.1 and MCM3AP-AS1, which suppress disulfidptosis and may serve as potential therapeutic targets for COAD.

show abstract

m6A-related lncRNAs are potential biomarkers for the prognosis of COAD patients

Cited by 4 publications

References 36 publications

Construction and validation of a metabolic-associated lncRNA risk index for predicting colorectal cancer prognosis

Construction and validation of a metabolic-associated lncRNA risk index for predicting colorectal cancer prognosis

The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer

Establishment of disulfidptosis-related LncRNA signature as biomarkers in colon adenocarcinoma

Contact Info

Product

Resources

About